[PDF] mdpi.com

Preclinical evaluation of the association of the cyclin-dependent kinase 4/6 inhibitor, ribociclib, and cetuximab in squamous cell carcinoma of the head and neck

G van Caloen, S Schmitz, C Van Marcke, X Caignet… - Cancers, 2021 - mdpi.com
Simple Summary We previously showed that ribociclib induces cell cycle arrest in some
human papillomavirus (HPV)-negative squamous cell carcinomas of the head and neck …
被引用次数：8 相关文章 所有 8 个版本
[PDF] uclouvain.be

Preclinical activity of ribociclib in squamous cell carcinoma of the head and neck

G Van Caloen, S Schmitz, M El Baroudi… - Molecular cancer …, 2020 - AACR
Cell-cycle pathway impairments resulting in CDK4 and 6 activation are frequently observed
in human papillomavirus (HPV)-negative squamous cell carcinoma of the head and neck …
被引用次数：24 相关文章 所有 9 个版本

Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

E Seront, S Schmitz, S Rottey, S Henry… - Annals of …, 2016 - annalsofoncology.org
Background The majority of Human Papilloma Virus (HPV)-negative squamous cell
carcinoma of the head and neck (SCCHN) has inactivation of p16, an inhibitor of the Cyclin …
被引用次数：3 相关文章 所有 2 个版本
[HTML] frontiersin.org

[HTML][HTML] Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous …

E Seront, S Schmitz, M Papier, A van Maanen… - Frontiers in …, 2019 - frontiersin.org
Background: The majority of human papillomavirus (HPV)-negative squamous cell
carcinoma of the head and neck (SCCHN) present upregulation of the epidermal growth …
被引用次数：19 相关文章 所有 11 个版本

The potential for selective cyclin-dependent kinase 4/6 inhibition in the therapy for head and neck squamous cell carcinoma

D Adkins, J Ley, J Cohen, P Oppelt - The Cancer Journal, 2022 - journals.lww.com
Preclinical data support investigation of selective CDK4/6 inhibition as a therapeutic strategy
for human papillomavirus (HPV)–unrelated head and neck squamous cell carcinoma …
被引用次数：4 相关文章 所有 5 个版本

An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in …

B Keam, M Tahara, JC Lin, AG Sacco, B Melichar… - 2016 - ascopubs.org
TPS6102 Background: SCCHN is the sixth most common cancer worldwide. Current second-
line treatments for human papillomavirus (HPV)–negative, R/M SCCHN have marginal …
被引用次数：3 相关文章

Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo

R Li, Q Wang, Y Zhao, Y Zhu, X Wang - Molecular Biology Reports, 2024 - Springer
Background In head and neck squamous cell carcinoma (HNSCC) with human
papillomavirus (HPV)-negative, deregulation of cell cycle is partly due to inactivation of …
相关文章 所有 3 个版本

Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized …

D Adkins, JC Lin, AG Sacco, JC Ley, P Oppelt, Q Shen… - 2019 - ascopubs.org
6013 Background: Cetuximab monotherapy results in a median overall survival (OS) of
approximately 6 months (mo) in platinum-resistant recurrent/metastatic head and neck …
被引用次数：19 相关文章

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 …

D Adkins, J Ley, P Neupane, F Worden… - The lancet …, 2019 - thelancet.com
Background Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16
INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin …
被引用次数：103 相关文章 所有 10 个版本

A phase I trial of the addition of the CDK 4/6 inhibitor palbociclib to cetuximab in patients with incurable head and neck squamous cell carcinoma (HNSCC).

LS Michel, JC Ley, TM Wildes, K Trinkaus, D Adkins - 2015 - ascopubs.org
6043 Background: Overexpression of cyclin D1 and inactivation of p16 occur in the majority
(> 90%) of HPV-unrelated HNSCC. Resistance to cetuximab and cisplatin, the two most …
被引用次数：6 相关文章